Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-389949

NCT02099071 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

65

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Subjects

Interventions

DRUG: ACT-389949 1 mg
DRUG: ACT-389949 5 mg
DRUG: ACT-389949 20 mg
DRUG: ACT-389949 50 mg
DRUG: ACT-389949 100 mg
DRUG: ACT-389949 200 mg
DRUG: ACT-389949 500 mg
DRUG: ACT-389949 1000 mg
DRUG: Placebo

Sponsor

Idorsia Pharmaceuticals Ltd.